Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials
Observational study reported manageable adverse events in patients treated with talquetamab, suggesting its safety profile aligns with clinical trials.
Key Points
Overall tolerance of talquetamab was high, with manageable adverse events like cytokine release syndrome and infections.
Data from 93 patients over a median follow-up of 15 months demonstrated that most adverse events were grade 1/2.
Observational analysis across multiple countries highlighted efficacy alongside overall safety profile consistent with previous studies.
Significant resolution of toxicities suggests further investigation into talquetamab's long-term safety is warranted.